



Pseudomonas aeruginosa (276/11): sc-80922

BACKGROUND

Pseudomonas aeruginosa is a Gram-negative, aerobic, rod-shaped bacterium with unipolar motility. It is an opportunistic pathogen of plants and humans and can infect the urinary tract, respiratory and gastrointestinal system, soft tissues, bones and joints leading to severe systemic infections of immunosuppressed patients in hospitals. *P. aeruginosa* secretes a variety of pigments, including pyocyanin (blue-green), Fluorescein (pyoverdine) and pyorubin (red-brown). This organism can achieve anaerobic growth with nitrate as a terminal electron acceptor, and, in its absence, it is also able to ferment arginine by substrate-level phosphorylation. Adaptation to microaerobic or anaerobic environments is essential for certain lifestyles of *P. aeruginosa*, such as during lung infection in cystic fibrosis patients where thick layers of alginate surrounding bacterial mucoid cells can limit the diffusion of oxygen. This antibody is specific for serotype 10 and does not react with other species tested.

REFERENCES

1. Boukraa, L. and Niar, A. 2007. Sahara honey shows higher potency against *Pseudomonas aeruginosa* compared to North Algerian types of honey. *J. Med. Food* 10: 712-714.
2. Harrison, F., Paul, J., Massey, R.C. and Buckling, A. 2008. Interspecific competition and siderophore-mediated cooperation in *Pseudomonas aeruginosa*. *ISME J.* 2: 49-55.
3. Pawar, M., Mehta, Y., Purohit, A., Trehan, N. and Daniel, R.V. 2008. Resistance in Gram-negative bacilli in a cardiac intensive care unit in India: risk factors and outcome. *Ann. Card. Anaesth.* 11: 20-26.
4. Muthu, K., He, L.K., Melstrom, K., Szilagyi, A., Gamelli, R.L. and Shankar, R. 2008. Perturbed bone marrow monocyte development following burn injury and sepsis promote hyporesponsive monocytes. *J. Burn Care Res.* 29: 12-21.
5. Jahoor, A., Patel, R., Bryan, A., Do, C., Krier, J., Watters, C., Wahli, W., Li, G., Williams, S.C. and Rumbaugh, K.P. 2008. Peroxisome proliferator activated receptors mediate host cell pro-inflammatory responses to *P. aeruginosa* autoinducer. *J. Bacteriol.* E-published ahead of print.
6. Dia, N.M., Ka, R., Dieng, C., Diagne, R., Dia, M.L., Fortes, L., Diop, B.M., Sow, A.I. and Sow, P.S. 2008. Prevalence of nosocomial infections in a university hospital (Dakar, Senegal). *Med. Mal. Infect.* E-published ahead of print.
7. Hocquet, D., Muller, A., Blanc, K., Plésiat, P., Talon, D., Monnet, D.L. and Bertrand, X. 2008. Relationship between antibiotic use and incidence of MexXY-OprM overproducers among clinical isolates of *Pseudomonas aeruginosa*. *Antimicrob. Agents Chemother.* E-published ahead of print.
8. Visscher, S., Schurink, C.A., Melsen, W.G., Lucas, P.J. and Bonten, M.J. 2008. Effects of systemic antibiotic therapy on bacterial persistence in the respiratory tract of mechanically ventilated patients. *Intensive Care Med.* E-published ahead of print.

STORAGE

Store at 4° C, **DO NOT FREEZE**. Stable for one year from the date of shipment. Non-hazardous. No MSDS required.

SOURCE

Pseudomonas aeruginosa (276/11) is a mouse monoclonal antibody raised against native *Pseudomonas aeruginosa* serotype 10.

PRODUCT

Each vial contains 100 µg IgG₃ in 1.0 ml of PBS with < 0.1% sodium azide and 0.1% gelatin.

APPLICATIONS

Pseudomonas aeruginosa (276/11) is recommended for detection of *Pseudomonas aeruginosa* serotype 10 of *Pseudomonas aeruginosa* origin by solid phase ELISA (starting dilution 1:30, dilution range 1:30-1:3000).

RESEARCH USE

For research use only, not for use in diagnostic procedures.

PROTOCOLS

See our web site at www.scbt.com or our catalog for detailed protocols and support products.